Three-drug combination therapy to prevent glucocorticoid-associated osteonecrosis in patients with systemic lupus erythematosus: a proof-of-concept study

Goro Motomura, Yojiro Arinobu, Hiroaki Niiro, Kazuoto Hiramoto, Yuko Kaneko, Masaru Kato, Shuhei Takeyama, Shunsuke Furuta, Hiroshi Nakajima, Ran Nakashima, Hajime Yoshifuji, Takeshi Kuroda, Koichi Amano, Masakazu Matsushita, Ken Yamaji, Koshiro Sonomoto, Yoshiya Tanaka, Naoko Himuro, Katsuhisa Miyake, Akihito Maruyama, Yoshifumi Tada, Atsushi Nomura, Masato Okada, Junji Kishimoto, Yasuharu Nakashima, Takuaki Yamamoto

Therapeutic Advances in Musculoskeletal Disease

Published online on February 23, 2026

Abstract

Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:Systemic lupus erythematosus (SLE) is a major underlying disease of glucocorticoid-associated osteonecrosis of the femoral head (ONFH). Despite its clinical significance, no prophylactic treatment has been established to prevent ONFH in ...